Does Cigna Cover AndroGel? Coverage Rules, Prior Auth, and Appeals Explained

What Does Cigna's Coverage Policy for AndroGel Actually Require?

Cigna covers AndroGel when a prescriber documents a confirmed diagnosis of male hypogonadism and submits a prior authorization (PA) request with supporting labs. Coverage is not automatic. The PA packet must show two separate serum total testosterone measurements below 300 ng/dL drawn before 10 a.m., plus at least one classic symptom such as decreased libido, erectile dysfunction, fatigue, or loss of lean body mass.

The Endocrine Society's 2018 clinical practice guideline recommends confirming low testosterone on two separate occasions before starting therapy, stating: "We recommend confirming the diagnosis by repeating the measurement of serum total testosterone." [1] Cigna's own medical policy language closely tracks this standard. Plans that use the Cigna National Formulary typically also require the prescriber to document that the low testosterone is not secondary to a reversible cause (such as opioid use, hyperprolactinemia, or obesity) before approving a branded gel product.

The T-Trials, a coordinated set of seven placebo-controlled trials in 788 men aged 65 or older with total testosterone below 275 ng/dL, provided some of the most rigorous efficacy data supporting testosterone replacement. Published in the New England Journal of Medicine in 2016, the sexual function trial found a mean testosterone increase from 232 ng/dL to 495 ng/dL with gel treatment, accompanied by a statistically significant improvement in sexual desire scores compared to placebo (P<0.001). [2] Insurers including Cigna cite this class of evidence when defining their coverage criteria.

AbbVie's AndroGel 1.62% gel received FDA approval for hypogonadism in adult males in 2011 and the full prescribing information is maintained in the FDA's Drugs@FDA database. [3] The label specifies that AndroGel is not approved for use in women or as a treatment for age-related testosterone decline in the absence of a diagnosed disorder. Cigna's policy mirrors this restriction: age-related decline alone, without a documented pathologic etiology, is typically denied.

What Formulary Tier Is AndroGel on Cigna?

Most Cigna commercial formularies place AndroGel 1.62% on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the specific plan year and employer group contract. Tier placement directly sets your copay or coinsurance.

On a standard Cigna Choice Fund or Open Access Plus plan, a Tier 3 brand copay often runs $80, $120 for a 30-day supply after the deductible is met. Tier 4 coinsurance of 40 to 50% on a $510 list price pushes that cost to $200 or more per fill. Generic testosterone cypionate injection (200 mg/mL vial) sits on Tier 1 or Tier 2 at $10, $25 per month, which is why Cigna frequently mandates a step-therapy trial of the injectable form first.

The FDA maintains a full list of approved testosterone replacement products. [4] Cigna's formulary team reviews this list annually. Tier assignments can change at each plan year, so confirming the current tier through Cigna's online formulary search tool or by calling the pharmacy benefits number on the insurance card before filling a new prescription is always worthwhile.

How Does Cigna's Prior Authorization Process Work for AndroGel?

Prior authorization for AndroGel on Cigna requires five documented elements: (1) a confirmed diagnosis of hypogonadism, (2) two morning total testosterone levels below 300 ng/dL from a CLIA-certified lab, (3) documentation of symptomatic presentation, (4) a ruling out of reversible causes, and (5) for some plans, evidence that the member tried and failed (or has a contraindication to) an injectable testosterone formulation.

The prescriber or their staff submits the PA through Cigna's provider portal (CignaforHCP.com), by fax, or via a pharmacy-initiated PA request from the dispensing pharmacy. Cigna is required by most state regulations and the ACA to provide an initial PA decision within 3 business days for non-urgent requests and 1 business day for urgent requests.

A 2022 JAMA Internal Medicine analysis found that prior authorization requirements delayed or abandoned treatment in a substantial proportion of cases and that PA denial rates for specialty and brand medications varied widely across commercial payers. [5] This background matters because AndroGel denials from Cigna are not uncommon, particularly when the PA packet lacks both qualifying testosterone levels or omits documentation of symptom burden.

The Endocrine Society guideline notes: "Clinicians should be aware that testosterone concentrations vary considerably and that a single low value may not accurately reflect a patient's true testosterone status." [1] Including both qualifying lab values in the PA submission, with collection times noted, reduces the chance of an administrative denial.

Once approved, most Cigna PA authorizations for AndroGel last 12 months. Renewals require updated labs confirming continued hypogonadism and, in some plans, documentation that the patient has responded to therapy or that symptoms have improved.

Does Cigna Require Step Therapy Before AndroGel?

Yes. Most Cigna commercial plans require a step-therapy trial of generic testosterone cypionate or testosterone enanthate injection before approving AndroGel or another branded topical gel. The rationale is cost: injectable generic testosterone typically costs $10, $30 per month versus $510 list price for AndroGel.

Step therapy is waivable in specific clinical circumstances. Accepted exceptions documented in Cigna's policy typically include:

• Documented adverse reaction to injections (e.g., post-injection pain syndrome, hematoma at injection site)
• Patient inability to self-inject and lack of caregiver support (documented in the medical record)
• A skin condition or occupational hazard that contraindicates topical gel but makes injection the only viable route (this is the reverse situation, so the exception applies when injection is contraindicated and gel is the only option)
• Physician attestation that an injection-based regimen would be clinically inappropriate for a specific, documented reason

Many states have enacted step-therapy reform laws that require insurers to honor a prescriber's clinical exception request within defined timeframes. As of 2024, more than 30 states have laws requiring insurers to offer a step-therapy exception process. [6] If your state has such a law, Cigna must respond to a formal exception request, and the prescriber's letter citing clinical necessity carries legal weight in that appeal.

How Do I Appeal a Cigna AndroGel Denial?

A Cigna denial of AndroGel coverage follows a defined, two-level internal appeal pathway before reaching external review. Acting promptly and with complete documentation at Level 1 gives the best chance of reversal.

Level 1 Internal Appeal. Submit within 180 days of the denial notice. The appeal packet should include: the original PA denial letter, both qualifying testosterone lab reports with collection times, a signed letter of medical necessity from the prescriber, clinical notes documenting symptoms, and any peer-reviewed citations supporting topical over injectable testosterone for this specific patient. Cigna must respond within 30 days for non-urgent benefit appeals and within 72 hours for urgent/concurrent care appeals.

Level 2 Internal Appeal. If Level 1 fails, request a Level 2 review. This goes to a different, senior Cigna medical reviewer. The same documentation applies; adding a one-page summary of why the Level 1 denial was clinically incorrect strengthens the packet.

Independent Review Organization (IRO). After exhausting internal appeals, members have the right to an external review by an independent organization under the ACA's external review provisions. [7] The IRO's decision is binding on Cigna. External review reversal rates for medication denials are meaningful: a 2023 analysis published on the CMS website found external reviewers overturned insurer decisions in approximately 40 to 60% of cases for certain drug categories.

The American Urological Association guidelines on male hypogonadism state that testosterone therapy is appropriate when testosterone is consistently below the normal range and symptoms are present. [8] Citing AUA guideline language directly in the appeal letter signals clinical rigor to the reviewing physician.

HealthRX Prior-Authorization and Appeal Checklist for AndroGel on Cigna

The following framework is designed for prescribers and patients navigating a first PA submission or first-level appeal.

1. Confirm both testosterone draws were collected between 7 a.m. and 10 a.m., on separate days, with results below 300 ng/dL from a CLIA-certified lab. LH and FSH should also be included to characterize primary versus secondary hypogonadism.
2. Document at least two symptoms from the Endocrine Society's recognized list: decreased libido, reduced energy, depressed mood, reduced lean mass, or erectile dysfunction.
3. Rule out reversible causes in the chart note. Mention opioid use, prolactin level, thyroid function, and BMI as evaluated variables.
4. For step-therapy waiver: provide a dated clinical note explaining why injectable testosterone is inappropriate for this patient, signed by the treating physician.
5. For the appeal packet: attach the AUA guideline paragraph supporting therapy, the T-Trials NEJM citation, and the patient's symptom response history if re-applying after a trial period.

What Does AndroGel Actually Cost With Cigna Coverage?

After a successful PA approval, the actual out-of-pocket cost depends on the plan tier, the deductible status, and whether a copay accumulator program is in effect.

• Tier 3 plans: $80, $120 per 30-day supply once the deductible is met
• Tier 4 plans: 40 to 50% coinsurance of approximately $510 list price, so $204, $255 per fill
• High-deductible health plans: full list price (~$510) until the annual deductible is met, then tier copay applies

For members who have not met their deductible, the cash-pay price through discount programs such as GoodRx or Cost Plus Drugs may actually be lower than the insurance price. Cash prices for AndroGel 1.62% at major pharmacy chains average $280, $380 per pump bottle depending on pharmacy and geography.

The FDA's Orange Book lists several authorized generic and branded testosterone gel products that may be substituted, some at lower cost. [4] Checking the specific formulary for a biosimilar or generic testosterone gel formulation approved by the FDA may open a Tier 1 or Tier 2 option without a PA requirement on some Cigna plans.

Can I Use the AndroGel Manufacturer Savings Card With Cigna?

For most Cigna commercial plan members, the AbbVie AndroGel savings card (which advertises out-of-pocket costs as low as $0, $10) is blocked by Cigna's copay accumulator or copay maximizer program. These programs prevent manufacturer coupon payments from counting toward the plan deductible or out-of-pocket maximum.

The National Academy for State Health Policy tracks state laws governing copay accumulators. [9] As of 2024, a smaller number of states restrict accumulator programs, but most Cigna commercial plans are ERISA-governed employer plans that fall outside state insurance law. Federal attempts to regulate accumulator programs in the ACA context remain ongoing and have faced court challenges.

If your plan does not use an accumulator program (typically the case for some smaller employer self-funded plans that have opted out), the manufacturer card may bring your monthly cost to $0 for 12 months. Call the pharmacy benefits number on your Cigna card and ask specifically whether your plan uses a copay accumulator or maximizer for specialty tier drugs before relying on the manufacturer card.

Step-Therapy Alternatives Cigna May Accept Instead of AndroGel

If Cigna denies AndroGel after step therapy fails or is not yet completed, several covered alternatives exist across different routes of administration.

Injectable testosterone. Testosterone cypionate 200 mg/mL (generic, Tier 1, 2) is the lowest-cost option. Patients self-administer subcutaneously or intramuscularly every 7 to 14 days. Fluctuating testosterone levels between injections are a common complaint. Testosterone enanthate is similarly priced and covered.

Other topical gels. Testim (testosterone 1%), Fortesta (testosterone 2%), and Vogelxo (testosterone 1%) are also brand topical gels that Cigna formularies cover with PA. Tier placement varies. Natesto, a testosterone nasal gel, sits on Tier 4 on most Cigna plans.

Testosterone pellets. Testopel (testosterone pellets) is covered by some Cigna plans but often with the same or higher PA burden and sometimes a non-covered procedure code for implantation. Confirm both the drug and the procedure code (CPT 11981) are covered before scheduling.

Clomiphene citrate (off-label). For secondary hypogonadism in men who wish to preserve fertility, clomiphene citrate is sometimes prescribed off-label at 25 to 50 mg every other day. Coverage is inconsistent across Cigna plans because the indication is off-label; however, the generic price is $30, $60 per month without insurance, making it a viable cash-pay alternative for select patients. The Endocrine Society guidelines do note selective estrogen receptor modulators as a treatment option for secondary hypogonadism. [1]

Monitoring Requirements Cigna May Require for Ongoing Coverage

PA renewals for AndroGel on Cigna typically require evidence of appropriate therapeutic monitoring. The Endocrine Society guideline recommends checking serum testosterone 3 to 6 months after starting therapy, then annually. [1] Cigna PA renewal criteria for most plans include at minimum an annual testosterone level confirming the patient remains in the hypogonadal range without treatment, or a note confirming the patient is responding symptomatically with treatment.

Additional monitoring labs that Cigna's clinical pharmacists may request at renewal include hematocrit (to screen for polycythemia, which should remain below 54%), PSA (for men over 40), and a brief clinical note on symptom response. The FDA labeling for AndroGel requires monitoring for polycythemia, sleep apnea, and changes in urinary symptoms. [3]

A hematocrit above 54% is a recognized safety threshold. The FDA label states that therapy should be interrupted if hematocrit rises above this level. [3] Documenting normal hematocrit and PSA in the PA renewal packet pre-empts the most common clinical hold reasons at renewal.

What If Cigna Denies AndroGel for a Non-Covered Indication?

Some Cigna members seek AndroGel for weight loss, muscle gain, or athletic performance rather than for diagnosed hypogonadism. Cigna does not cover AndroGel for these indications. The FDA has not approved testosterone replacement for weight loss, body composition improvement in eugonadal men, or any purpose other than classical or functional male hypogonadism and delayed puberty. [3]

Weight management indications are addressed by a separate class of agents. The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo. [10] Cigna covers semaglutide (Wegovy) for obesity under separate PA criteria tied to BMI and comorbidity thresholds, not testosterone status.

Prescribers who document an off-label indication on a PA request for AndroGel will trigger an automatic denial and may flag the member's account for heightened scrutiny on future requests. Writing the ICD-10 code E29.1 (testicular hypofunction) and documenting the confirmatory lab values is the correct pathway.